Bladder Cancer Trial, Recruiting NCT06349642 Sponsor: Mayo Clinic Condition: Bladder Cancer
Back to Bladder Cancer

Bladder Cancer Trial, Recruiting

NCT06349642
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with, or are suspected of having, an advanced or metastatic cancer that includes certain types — such as non-small cell lung cancer, skin cancer (not uveal melanoma), esophageal, cervical, endometrial, liver, or colon cancer (a specific type only) — or any solid tumor with certain genetic features (high mutation burden, MSI-H, or dMMR) (confirm with trial site for your specific cancer type).
  • You have advanced or metastatic kidney cancer (clear cell type) or bladder cancer, or any solid tumor that your doctor plans to treat with immunotherapy (sometimes called checkpoint inhibitor therapy).
  • You have early-stage, operable triple negative breast cancer or non-small cell lung cancer, and your doctor plans to give you immunotherapy before surgery.
  • Your cancer can be measured by scans or imaging (not by physical exam alone), and any area previously treated with radiation does not count as measurable disease.
  • If you are receiving immunotherapy before surgery, your doctor has confirmed you are eligible for this treatment.
  • If you are newly diagnosed or your cancer is suspected, you have not received any cancer treatment yet at the time of the biopsy.
  • If your cancer has progressed from an earlier stage to advanced/metastatic, you have stopped any previous cancer treatment at least 2–4 weeks before the biopsy (the exact time depends on what treatment you received).
  • You are generally well enough to carry out daily activities, with little to no limitation (a standard health scoring system is used to measure this — confirm with trial site).
  • If you could become pregnant, you must have a negative pregnancy test within 7 days before joining the trial, and you must use appropriate contraception.
  • You are willing and medically able to have either extra tissue samples taken during a routine biopsy, or a separate research-only biopsy.
  • If you have a second cancer diagnosis, it does not interfere with the treatment plan for your main cancer.
  • You are willing and able to sign a consent form agreeing to take part.

Who may not be able to join:

  • You are currently pregnant, because the biopsy procedure involved carries more than minimal risk.
  • You have other serious ongoing illnesses or health conditions that, in your doctor's opinion, would make participation unsafe or affect the results.
  • You have a weakened immune system, or you are HIV positive and currently taking antiretroviral medication — however, if you are HIV positive but do not show signs of a weakened immune system, you may still be eligible (confirm with trial site).
  • You have an uncontrolled or active infection, or a mental health or personal situation that would make it difficult to follow the study requirements.
  • You are already enrolled in, or planning to join, another cancer treatment trial where neither you nor the research team knows which treatment you are receiving (a "blinded" trial).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dev Mukhopadhyay, PhD, Mayo Clinic

Phone: 855-776-0015

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
24 April 2024
Est. completion
1 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Accuracy of the Elephas Score for predicting clinical response in neoadjuvant patients; Accuracy of the Elephas Score for predicting clinical response in locally advanced/metastatic patients

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov